Cilta-Cel Yields High Response Rates in R/R Multiple Myeloma: Saad Z. Usmani, MD, MBA, FACP
The director of Clinical Research in Hematologic Malignancies at Levine Cancer Institute discussed overall response rate and stringent complete responses in the CARTITUDE-1 trial.
Safety Profile of Cilta-Cel: Saad Z. Usmani, MD, MBA, FACP
The director of Clinical Research in Hematologic Malignancies at Levine Cancer Institute discussed adverse events in the CARTITUDE-1 trial.
Dr. Usmani on CAR T Cells, Bispecific Antibodies, and ADCs in Multiple Myeloma
Saad Z. Usmani, MD, FACP, discusses the mechanisms of action of BCMA-targeted CAR T-cell therapy, bispecific monoclonal antibodies, and antibody-drug conjugates in multiple myeloma.